Sofosbuvir impurity E

• CAT Number: I013102
• Molecular Formula: C₂₂H₂₉FN₃O₉P
• Molecular Weight: 529.45
• Purity: ≥95%
• Target: Drug Metabolite
• Solubility: DMSO
• IUPAC Name: propan-2-yl (2S)-2-[[[(2R,3S,4S,5R)-5-(2,4-dioxopyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyloxolan-2-yl]methoxy-phenoxyphosphoryl]amino]propanoate
• InChI: InChI=1S/C22H29FN3O9P/c1-13(2)33-19(29)14(3)25-36(31,35-15-8-6-5-7-9-15)32-12-16-18(28)22(4,23)20(34-16)26-11-10-17(27)24-21(26)30/h5-11,13-14,16,18,20,28H,12H2,1-4H3,(H,25,31)(H,24,27,30)/t14-,16+,18-,20+,22-,36-/m0/s1
• InChIKey: TTZHDVOVKQGIBA-VZZHANGQSA-N
• SMILES: CC(C)OC(=O)C(C)NP(=O)(OCC1C(C(C(O1)N2C=CC(=O)NC2=O)(C)F)O)OC3=CC=CC=C3

Sofosbuvir Impurity E(CAT: I013102) is a related substance identified during the synthesis or degradation of Sofosbuvir, an antiviral medication used to treat chronic hepatitis C. Structurally similar to Sofosbuvir, Impurity E is significant in pharmaceutical research, particularly for evaluating the quality, safety, and stability of the drug. Its identification, quantification, and characterization are crucial for adhering to regulatory guidelines and ensuring drug efficacy. This impurity is also used as a reference standard in analytical method development, supporting studies on Sofosbuvir’s production processes and degradation pathways, which are critical for quality control and drug development efforts.